Jefferies reiterates Buy on Nektar stock after alopecia trial data

Nektar’s Phase 2 REZOLVE-AA data showed approximately 28% of patients achieved SALT scores below 20 at Week 52 on the 24µg/kg dose, topping the company’s 20-25% expectation and matching Oppenheimer’s 25-30% best-case range. Safety remained consistent, and the company plans an end-of-Phase 2 meeting in Q2 plus 24-week off-treatment data in Q4. Analyst views remain constructive, with Jefferies at Buy/$121, Oppenheimer at Outperform/$140, and Wedbush initiating at Neutral/$70.

Analysis

NKTR is starting to look less like a binary biotech and more like a late-stage catalyst trade with a credibility problem. The core shift is not the headline response rate; it is the durability signal into week 52, which makes the asset more fundable and meaningfully improves the probability of partnering or financing on better terms. That matters because in a crowded alopecia market, a therapy that can show persistence without obvious safety degradation has a better shot at conversion into a commercial narrative, even if it is still behind the most relevant current standard.

Second-order, the read-through is harsher for any company leaning on weaker long-duration autoimmune differentiation: the market will now demand not just early response but maintenance and off-treatment persistence. That raises the bar for peers in dermatology and immunology where efficacy is often front-loaded but retention is the real value driver. If NKTR’s data continue to hold, the likely medium-term winner is the company’s negotiating leverage, while the loser is any competitor depending on “good enough” mid-teens response rates with less durability.

The main risk is that this stock has likely pulled forward a lot of the good news already. With the shares so extended, the next move may depend more on whether management can turn data into a credible regulatory and partnering pathway over the next 1-2 quarters than on another incremental efficacy print. Any hint of plateauing, tolerability drift, or a benchmark reset toward tougher comparators could compress the multiple quickly because the market is paying for a premium probability of success, not just a decent trial.

The contrarian angle is that investors may be over-indexing on the percentage response and underpricing the commercial hurdle. Alopecia is emotionally compelling, but payer willingness, long treatment duration, and patient persistence will decide whether this becomes a real franchise or just a high-volatility catalyst name. If the upcoming off-treatment data show drop-off, the market may rerate the asset from ‘platform winner’ to ‘interesting but niche,’ which would be a meaningful de-rating even if the biology stays intact.

Key Decisions for Investors

• Take profits in NKTR into strength over the next 1-3 sessions; the asymmetry has shifted from rerating to execution risk, and the stock likely needs a fresh catalyst to justify further multiple expansion.
• If maintaining exposure, finance it with a call spread rather than outright equity: buy near-dated calls and sell a higher strike 1-2 standard deviations out to capture upside into the end-of-Phase-2 meeting while limiting downside from post-news mean reversion.
• Watch for a partner/financing announcement in the next 1-2 quarters; if one emerges on favorable terms, re-enter on the first pullback as that would validate the durability thesis and de-risk commercialization.
• Relative-value idea: short a basket of weaker autoimmune/dermatology names with less durability evidence against NKTR only if NKTR stalls on the next data release; otherwise the cleaner trade is a tactical long/flat rather than a pair.